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It is well known that carcinoma of the breast is a relatively common condition occurring in about 1 woman in 17and being responsible for about 10%of all female deaths from cancer. As a radiotherapist I have been interested in cancer of the breast for many years, as well as being extensively involved in the care of patients with this disease. The title of this address was chosen to reflect the fact that, during the approximately 50 years since the Section ofRadiology within the RSM was formed from the previous Section of Electrotherapeutics, there has been a considerable number of meetings devoted to carcinoma of the breast.
Few would disagree with the suggestion that the major problems in patients with cancer, perhaps particularly of the breast, relate to metastases, their time of appearance and location, the mechanisms which lead to their development, their detection and their response to treatment. A meeting of this Section was held in January 1935 under the title, 'Discussion on the Prevention and Treatment of Metastases in Carcinoma Mammae'. Almost two generations later we are still unable to prevent metastases and there is no universal agreement as to their treatment. In that meeting Todd (1934-35) explained his theory of the development of cancer and metastases in relation to a local tissue defence mechanism which at some stage was diminished by an unknown occurrence, perhaps exhaustion of the patient, and unchecked growth was the result. The phenomenon of secondary spread becoming apparent in times of emotional stress is now well recognized. Todd advised the local injection of colloidal selenium associated with low doses of X-rays to boost the defence mechanism, particularly in the prophylactic care of the supposed surgical cure where treatment at intervals over a year was advised. The parallel with modem prophylactic adjunctive cytotoxic chemotherapy for minimal residual disease is clear.
At the same meeting Scott (1934-35) suggested that the only safe basis for treatment if a cure was to be found must be the assumption that metastases have established themselves in every case in which the diagnosis of cancer has been made, and recognized the need for a test to monitor progress. He suggested serial estimations of the serum vanadic acid, and again it is difficult to avoid a comparison with the use in more modem practice of estimations such as that of CEA in monitoring the progress of patients. Finzi (1934-35) emphasized the view that any procedure intended to be curative, such as the so-called prophylactic irradiation after a surgical removal, was really a treatment of possible small metastatic remnants for which it was essential to give full cancericidal dose.
Thus in the 1930s, some of the questions which still plague those of us required to advise patients with carcinoma of the breast had already been raised, such as the method of origin and formation of secondary deposits, and therefore the question as to whether there is any possibility of avoiding them; the time in the natural history of the disease at which metastases may develop and become apparent; the effectiveness of treatment and ofmonitoring its results and indeed the effect of treatment on survival. There was also disagreement between different practitioners as to the appropriate treatment in any given situation. It was also well recognized that there are changes in fashions of treatment which lead to the not uncommon situation in which a proponent of a form of treatment is asked some years later about progress in the field and his answer is that he is no longer using that particular regime.
In January 1943 Cade reached the conclusion that skilled radiotherapy was no longer an auxiliary method, but of equal and in some cases greater importance than surgery. McWhirter put forward the philosophy which led to the method of treatment associated with his name. His preliminary investigations had led him to the conclusions that in the performance of the radical operation for carcinoma of the breast, malignant cells were often left behind in the area which could be treated by radiotherapy; that effective postoperative radiotherapy reduced the local recurrence rate; and that by reducing the local recurrence rate many potential failures were converted into successes and the three-year symptom free rate was materially raised. While agreeing with much of what he suggested, I think there might now be doubts expressed as to whether the control oflocal recurrence is reflected in success as measured by long-term control of the disease and survival.
It is very easy for us to be wise after the event, but one cannot help thinking that progress might have been much quicker if McWhirter had then carried out, within Edinburgh, a random comparison of his method of treatment with another. At least it would probably have eliminated the delay of almost thirty years before his approach was generally accepted as being as effective as radical mastectomy. It should also be remembered that he warned that his method of treatment of carcinoma of the breast should not be adopted in other centres until its value had been determined.
The normal breast is an organ subject to extreme changes, both macroscopic and microscopic, under the influences of changes in circulating hormones; and further, it has been known for many years that in patients with carcinoma of the breast such events as pregnancy or the menopause are frequently related to rapid changes in the tumour. At a meeting in June 1944a total of 168cases of advanced cancer of the breast treated by stilboestrol were reported. Some 47 had shown some improvement, with 6 spectacular responses. During that meeting, Haddow (1943-44) suggested that the differences in response between different patients might indicate that carcinoma of the breast was not a uniform disease, the same in all patients, thus possibly foreshadowing the recognition of receptors in the cells of some cancers of the breast which may help to explain the responses to different treatments and possibly help to select the patients more accurately for treatment.
In 1948 Gordon-Taylor reported his lifetime work as a surgeon interested in cancer of the breast and expressed his philosophy as preferring 'a sharp knife, a stout heart, and unquenchable optimism together with the widest possible radical surgery untramelled by ancillary radiation '. McWhirter (1948) commented on some limitations of Gordon-Taylor's approach; he reported some of the early results of his policy of management in Edinburgh, introducing the concept of assessing the contribution made by a policy of treatment to the whole spectrum of that particular disease in a geographical population rather than in a limited or selected group of patients. It is, of course, essential to select whichever method of treatment is best for the individual patient and it may be equally invalid to say that conservative mastectomy and radiotherapy should be advised for all patients, as it would be to say that radical mastectomy should be advised. It is, of course, also essential that the highest standard of treatment by whichever method that may be indicated and accurate record-keeping are both vital.
It is sad to have to recall that a further twenty years would pass before there was an extensive national trial in Britain of treatment of carcinoma of the breast; this was the first Cambridge King's Trial started by Professors Mitchell and Murray who were able to persuade a large number of surgeons and radiotherapists to agree to the trial of two equally acceptable forms of treatment which differed sufficiently in principle to make a valid trial (see Cancer Research Campaign Working Party 1980) . In 1950Stoll emphasized the differential effect sometimes seen in different sites ofsecondary tumour in the same patient, and in 1960 both Atkins and Falconer demonstrated that either bilateral adrenalectomy or hypophysectomy was effective in a similar proportion of patients with advanced disease and again emphasized the necessity for meticulous technique and selection of patients.
At about that time I was involved personally in a small study to compare bilateral adrenalectomy with the administration of thiotepa and Deca-Durabolin in patients with advanced disease and, at about the same time, in methods of ablating the pituitary gland by interstitial radiation, in the absence of any surgeons in Newcastle interested in the surgical ablation of the pituitary gland. The fact that no definite preference for either thiotepa or adrenalectomy was demonstrated may have been due, at least in part, to some difficulty in the selection of patients in the absence, for example, of receptor analysis; but this was also an early example of competition between hormone manipulation and cytotoxic drug therapy for patients with extensive metastatic disease. The question is still unresolved but there has been some preference for the cytotoxic approach.
In October 1957 , Bloom (1958 presented a paper on the value of histology in the classification and prognosis of breast cancer, with particular reference to the variable progress of patients with apparently similar cancers, and again suggested that breast cancer was, in fact, a group of tumours with a broad spectrum of malignancy. He suggested that neither histological grading nor anatomical staging was necessarily very helpful individually in indicating the likely prognosis for the given patient and suggested the concept of a prognostic index, taking into account both grading and staging as being more valuable than either alone. This concept has, of course, been developed further subsequently and it is possible that the more factors, such as indicators of distant spread, the presence of biochemical markers or steroid receptors or, more arguably, the impairment of defence mechanisms, which can be introduced into the assessment of the index, the greater will be its value. It has, of course, been shown that some factors are interdependent and the majority of formulae for prognostic indices includes a degree of relevant weighting of the different factors. In this connection, I would like to express my own personal surprise about one such factor, namely, whether less or more than 4 axillary nodes are found microscopically to be the site of tumour, because it does not appear to be associated with the thoroughness of the examination of the individual nodes nor, indeed, with the total number of nodes found or examined, and yet statistically it does appear to correlate relatively well with prognosis.
In subsequent years the topics considered at meetings tended to relate more to the detection and treatment of the disease in the earlier stages of its natural history. In 1959 Gillies discussed the need for removal of the whole breast and the possibility of surgical replacement, instead ofor in relation to an external prosthesis. The arguments raised at that time are still continuing, with special reference to the possibility ofleaving behind foci of tumour, particularly in those patients where the neoplasm is initially multifocal, the extent to which the partially removed breast is cosmetically acceptable to the patient and to her husband, and the theoretical concern that a surgical replacement may delay detection of local recurrences. It would probably be more readily accepted now than twenty years ago that such delay in the detection of local recurrence is less critical in terms of long-term cure than would be the case for distant metastases, and one hears much less frequently now the argument of multifocal origin against the pleas for conservative surgery. This may be because it is now acknowledged that much more information is required concerning the natural history of possible preclinical or subclinical abnormalities, noted on histological examination of breast tissue removed to some extent prophylactically as, for example, in total mastectomy for a very small primary tumour.
In 1963 the discussion was centred on the detection of early disease by mammography with special reference to the difficulties caused by (1) the fact that mammography was looking for 'early' though established cancer rather than pre-eancer; (2) how one defined 'early'; and (3) the absolute accuracy and cost benefit effectiveness of mammography. Young (1963) concluded that the diagnosis of preclinical unsuspected carcinoma of the breast was feasible with a small pick-up rate and that logistically and technically such a service was possible. The subject of early cancer and its detection' was again discussed in 1970 in relation to the definition of early cancer and whether it should be detected by the patient herself or by mammographic examinations, together with the question of the incidence of false negatives and false positives and their relative importance. Can cancer of the breast be detected sufficiently early by mammography, clinical screening and/or self-examination to increase the chance of cure? The answer is almost certainly 'yes', though not to 100%, and it is dependent on repeated screening at least twice a year. Furthermore, in the case ofself-examination a high degree of honesty on the part of the patient is assumed. The problems raised by false reports are, of course, different in that a false positive report will cause alarm temporarily until negative biopsy is obtained, whereas a false negative report will lead to a false sense of security and possibly immeasurable delay before further assessment and diagnosis. At this meeting also, Forrest emphasized the importance of accurate diagnosis of the extent of the disease, so that all of the affected tissues, but no associated normal tissues, should be treated. He suggested that nothing less than total local mastectomy should be considered and reaffirmed the importance of axillary node involvement as a prognostic index (Forrest et al. 1970) .
In 1973 Sutton reported the experience at the Hammersmith Hospital in the development of a regime of multiple cytotoxic agents which had been shown to have a reasonable therapeutic effect with acceptable associated toxicity. Although his experience referred to the therapeutic use of cytotoxic agents in established metastatic disease, he was already postulating the potential value of prophylactic treatment in apparently early and limited cases, and also raising the query as to whether there might be late effects resulting from such treatment. Already the story had come almost full circle since the meeting in 1935 when the possibility of preventing the clinical development of occult metastases was discussed. While there can be no doubt that cytotoxic chemotherapy for established metastatic disease is effective, and often effective in situations where other treatments are of no specific avail, it is still distressing to see somewhat extravagant claims made for prophylactic adjunctive cytotoxic chemotherapy with follow-up periods of less than 5 years.
There was a further meeting concerning mammography and the establishment of a population screening programme in 1975,when questions which still required an answer were considered to be: 'Is mammography safe?' 'Can clinical screening be done by non-medical staff?' 'Do women want it?' 'Can the hospitals cope with the additional workload involved?' It will probably now be accepted that by using techniques designed to reduce exposure to radiation and by concentrating on postmenopausal patients, the incidence of induced tumours is less than the pick-up rate of occult disease; that trained and dedicated nurses and radiographers can be as effective as surgeons, radiotherapists and radiologists in detecting important abnormalities in the breast; that about half of the so-called occult tumours can be detected by self-examination and clinical examination, with a further small dividend from added mammography; and that in most teaching hospitals with academic departments of surgery and radiology, the associated workload is not a serious problem. But there is still a question mark about the acceptability to women as a whole of a screening programme and there is probably a real doubt as to whether, in a peripheral district hospital, either the radiologist or the surgeon can always cope with the additional responsibility of a screening programme.
It follows naturally from reference to that 1975 meeting to mention screening of patients with known primary carcinoma ofthe breast, with a view to assessing the extent of metastatic disease; and you will not need to be reminded of the range of investigations which have been advocated to assess in patients with ostensibly early disease the presence of distant spread which would convert their diagnosis from Stage I to Stage IV. It is perhaps natural to think primarily of radioisotope bone scanning, but other similar programmes include liver and brain scanning and hydroxyproline estimations. While there is no doubt that a proportion of patients with clinically early disease will be shown by these various methods to have metastatic deposits, there is much less agreement that the detection of such deposits should lead to a change in management, or be likely to effect an improvement in their ultimate outlook. I think that one must accept the philosophy that some screening methods may demonstrate primary tumours or secondary deposits which will never become clinically important and are therefore possibly of doubtful significance to the clinician responsible for making a decision about treatment policy. It may be said of any screening programme for occult primary or metastatic disease that it should enable the clinician to identify about 80%of the relevant patients within a high-risk group of say 20%; I am not aware of any system, whether clinical, radiological or biochemical, which satisfies this criterion.
In 1976 Neville discussed the value of tumour marker substances and analysed his experience in monitoring the level of some 19such substances in relation to the natural history of the disease in individual patients (Coombes et al. 1977) . He reached the conclusion that though none of the substances studied were absolutely specific for breast cancer, nor present in all patients with the disease, useful information could be gained by serial estimations of a limited number of substances; in this way it might be possible to gain earlier warning of the development of metastases, though there remains the question of their exact location and the possible applicability of local as opposed to systemic treatment when evidence of recurrent tumour is obtained in this way. It is natural to refer back to the earlier reference to the levels ofvanadic acid in the serum rather more than 40 years before (Scott 1934-35) .
In this brief survey of the issues raised by the many patients who have developed carcinoma of the breast, I realize that some have been ignored completely, such as the psychological effects of the diagnosis and treatment on the patient and oflocal recurrence on the patient and the surgeon concerned; the possible immunological aspects; and the question of the appropriate timing of prophylactic treatment in relation to the ultimate effects on the outcome of the disease. There are yet others to which I will refer very briefly and really only to raise questions. For example, I wonder whether the justifiable enthusiasm and improvement in results which has followed intensive investigation and associated treatment of Hodgkin's disease has led to an expectation that similar improvement might follow in other forms of cancer, and one wonders why this has not been the case in carcinoma of the breast. The concept of a time at which it can be said that surviving patients are cured of their disease is, undoubtedly, postponed for over twenty years in the case of carcinoma of the breast, and may not, in fact, ever arise. Certainly the time at which it occurs has been put further and further back by different reporters. A recent review suggested that in the considerable number of patients who live for more than 10 years, the initial staging is of little importance (Langlands et al. 1979) . It is tempting to speculate that one reason why second tumours in organs other than the uterus are rare in patients who have had treatment for carcinoma of the breast is that the initial disease may not have been completely cured. This leads automatically to the query as to when the results of any form of treatment should be reported. I think there is genuine concern that in a disease where even lO-year results of survival with or without disease are certainly not premature, reports are seen regularly of two or three year results of the effects of prophylactic adjunctive therapy using cytotoxic agents or hormonal preparations. Another feature leading to some difficulty is that of tailoring the initial treatment of the disease to the exact type and extent of tumour in individual patients, and there is still need for additional information to help clinicians to be always in a position to advise the optimum treatment.
